Therapy of vector-borne protozoan infections in nonendemic settings

References

• Hay SI, Guerra CA, Gething PW et al. A world malaria map: Plasmodium falciparum endemicity in 2007. PLoS Med.6(3), e1000048 (2009).
   PubMed Web of Science ®Google Scholar
• Lescure FX, Le Loup G, Freilij H et al. Chagas disease: changes in knowledge and management. Lancet Infect. Dis.10(8), 556–570 (2010).
   PubMedGoogle Scholar
• Brun R, Blum J, Chappuis F, Burri C. Human African trypanosomiasis. Lancet375(9709), 148–159 (2010).
   PubMed Web of Science ®Google Scholar
• Bottieau E, Clerinx J, Schrooten W et al. Etiology and outcome of fever after a stay in the tropics. Arch. Intern. Med.166(15), 1642–1648 (2006).
   PubMed Web of Science ®Google Scholar
• Freedman DO, Weld LH, Kozarsky PE et al. Spectrum of disease and relation to place of exposure among ill returned travelers. N. Engl. J. Med.354(2), 119–130 (2006).
   PubMed Web of Science ®Google Scholar
• Hotez PJ, Molyneux DH, Fenwick A et al. Control of neglected tropical diseases. N. Engl. J. Med.357(10), 1018–1027 (2007).
   PubMedGoogle Scholar
• Moran M. A breakthrough in R&D for neglected diseases: new ways to get the drugs we need. PLoS Med.2(9), e302 (2005).
   PubMed Web of Science ®Google Scholar
• Muhlberger N, Jelinek T, Behrens RH et al. Age as a risk factor for severe manifestations and fatal outcome of falciparum malaria in European patients: observations from TropNetEurop and SIMPID Surveillance Data. Clin. Infect. Dis.36(8), 990–995 (2003).
   PubMed Web of Science ®Google Scholar
• Greenwood BM, Bojang K, Whitty CJ, Targett GA. Malaria. Lancet365(9469), 1487–1498 (2005).
   PubMed Web of Science ®Google Scholar
• Singh B, Kim SL, Matusop A et al. A large focus of naturally acquired Plasmodium knowlesi infections in human beings. Lancet363(9414), 1017–1024 (2004).
   PubMed Web of Science ®Google Scholar
• World Health Organization. Guidelines for the Treatment of Malaria, Second Edition. World Health Organization, Geneva, Switzerland (2010).
   Google Scholar
• Genton B, D’Acremont V, Rare L et al. Plasmodium vivax and mixed infections are associated with severe malaria in children: a prospective cohort study from Papua New Guinea. PLoS Med.5(6), e127 (2008).
   PubMed Web of Science ®Google Scholar
• Price RN, Tjitra E, Guerra CA et al. Vivax malaria: neglected and not benign. Am. J. Trop. Med. Hyg.77(Suppl. 6), 79–87 (2007).
   PubMed Web of Science ®Google Scholar
• Cox-Singh J, Davis TM, Lee KS et al. Plasmodium knowlesi malaria in humans is widely distributed and potentially life threatening. Clin. Infect. Dis.46(2), 165–171 (2008).
   PubMed Web of Science ®Google Scholar
• Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature434(7030), 214–217 (2005).
   PubMed Web of Science ®Google Scholar
• Mali S, Steele S, Slutsker L, Arguin PM. Malaria surveillance – United States, 2008. MMWR Surveill. Summ.59(7), 1–15 (2010).
   PubMedGoogle Scholar
• Jelinek T, Schulte C, Behrens R et al. Imported falciparum malaria in Europe: sentinel surveillance data from the European network on surveillance of imported infectious diseases. Clin. Infect. Dis.34(5), 572–576 (2002).
   PubMed Web of Science ®Google Scholar
• Wilson ME, Weld LH, Boggild A et al. Fever in returned travelers: results from the GeoSentinel Surveillance Network. Clin. Infect. Dis.44(12), 1560–1568 (2007).
   PubMed Web of Science ®Google Scholar
• Bruneel F, Tubach F, Corne P et al. Severe imported falciparum malaria: a cohort study in 400 critically ill adults. PLoS ONE5(10), e13236 (2010).
   Web of Science ®Google Scholar
• Hawkes M, Kain KC. Advances in malaria diagnosis. Expert Rev. Anti Infect. Ther.5(3), 485–495 (2007).
   PubMed Web of Science ®Google Scholar
• Marx A, Pewsner D, Egger M et al. Meta-analysis: accuracy of rapid tests for malaria in travelers returning from endemic areas. Ann. Intern. Med.142(10), 836–846 (2005).
   PubMed Web of Science ®Google Scholar
• Van der Palen M, Gillet P, Bottieau E et al. Test characteristics of two rapid antigen detection tests (SD FK50 and SD FK60) for the diagnosis of malaria in returned travellers. Malar. J.8, 90 (2009).
   PubMedGoogle Scholar
• Baird JK. Effectiveness of antimalarial drugs. N. Engl. J. Med.352(15), 1565–1577 (2005).
   PubMed Web of Science ®Google Scholar
• White NJ. The treatment of malaria. N. Engl. J. Med.335(11), 800–806 (1996).
   PubMed Web of Science ®Google Scholar
• White NJ, Olliaro PL. Strategies for the prevention of antimalarial drug resistance: rationale for combination chemotherapy for malaria. Parasitol. Today12(10), 399–401 (1996).
   PubMedGoogle Scholar
• Brockman A, Price RN, van Vught M et al. Plasmodium falciparum antimalarial drug susceptibility on the north-western border of Thailand during five years of extensive use of artesunate–mefloquine. Trans. R. Soc. Trop. Med. Hyg.94(5), 537–544 (2000).
   PubMed Web of Science ®Google Scholar
• Patel SN, Kain KC. Atovaquone/proguanil for the prophylaxis and treatment of malaria. Expert Rev. Anti Infect. Ther.3(6), 849–861 (2005).
   PubMedGoogle Scholar
• Bouchaud O, Monlun E, Muanza K et al. Atovaquone plus proguanil versus halofantrine for the treatment of imported acute uncomplicated Plasmodium falciparum malaria in non-immune adults: a randomized comparative trial. Am. J. Trop. Med. Hyg.63(5–6), 274–279 (2000).
   PubMed Web of Science ®Google Scholar
• Bottieau E, Clerinx J, Colebunders R et al. Selective ambulatory management of imported falciparum malaria: a 5-year prospective study. Eur. J. Clin. Microbiol. Infect. Dis.26(3), 181–188 (2007).
   PubMed Web of Science ®Google Scholar
• Thybo S, Gjorup I, Ronn AM, Meyrowitsch D, Bygberg IC. Atovaquone–proguanil (malarone): an effective treatment for uncomplicated Plasmodium falciparum malaria in travelers from Denmark. J. Travel. Med.11(4), 220–223 (2004).
   PubMed Web of Science ®Google Scholar
• Chiodini PL, Conlon CP, Hutchinson DB et al. Evaluation of atovaquone in the treatment of patients with uncomplicated Plasmodium falciparum malaria. J. Antimicrob. Chemother.36(6), 1073–1078 (1995).
   PubMed Web of Science ®Google Scholar
• Fivelman QL, Butcher GA, Adagu IS, Warhurst DC, Pasvol G. Malarone treatment failure and in vitro confirmation of resistance of Plasmodium falciparum isolate from Lagos, Nigeria. Malar. J.1, 1 (2002).
   PubMedGoogle Scholar
• David KP, Alifrangis M, Salanti A, Vestergaard LS, Ronn A, Bygbjerg IB. Atovaquone/proguanil resistance in Africa: a case report. Scand. J. Infect.Dis.35(11–12), 897–898 (2003).
   PubMedGoogle Scholar
• Farnert A, Lindberg J, Gil P et al. Evidence of Plasmodium falciparum malaria resistant to atovaquone and proguanil hydrochloride: case reports. Br. Med. J.326(7390), 628–629 (2003).
   PubMedGoogle Scholar
• Kuhn S, Gill MJ, Kain KC. Emergence of atovaquone–proguanil resistance during treatment of Plasmodium falciparum malaria acquired by a non-immune north American traveller to west Africa. Am. J. Trop. Med. Hyg.72(4), 407–409 (2005).
   PubMed Web of Science ®Google Scholar
• Schwobel B, Alifrangis M, Salanti A, Jelinek T. Different mutation patterns of atovaquone resistance to Plasmodium falciparum in vitro and in vivo: rapid detection of codon 268 polymorphisms in the cytochrome b as potential in vivo resistance marker. Malar. J.2, 5 (2003).
   PubMed Web of Science ®Google Scholar
• Wichmann O, Muehlen M, Gruss H, Mockenhaupt FP, Suttorp N, Jelinek T. Malarone treatment failure not associated with previously described mutations in the cytochrome b gene. Malar. J.3, 14 (2004).
   PubMedGoogle Scholar
• Musset L, Bouchaud O, Matheron S, Massias L, Le Bras J. Clinical atovaquone–proguanil resistance of Plasmodium falciparum associated with cytochrome b codon 268 mutations. Microbes Infect.8, 2599–2604 (2006).
   PubMedGoogle Scholar
• Sutherland CJ, Laundy M, Price N et al. Mutations in the Plasmodium falciparum cytochrome b gene are associated with delayed parasite recrudescence in malaria patients treated with atovaquone–proguanil. Malar. J.7, 240 (2008).
   PubMed Web of Science ®Google Scholar
• Schwartz E, Bujanover S, Kain KC. Genetic confirmation of atovaquone–proguanil-resistant Plasmodium falciparum malaria acquired by a nonimmune traveler to East Africa. Clin. Infect. Dis.37(3), 450–451 (2003).
   PubMed Web of Science ®Google Scholar
• Rose GW, Suh KN, Kain KC, Le Saux N, McCarthy AE. Atovaquone–proguanil resistance in imported falciparum malaria in a young child. Pediatr. Infect. Dis. J.27(6), 567–569 (2008).
   PubMedGoogle Scholar
• Savini H, Bogreau H, Bertaux L et al. First case of emergence of atovaquone–proguanil resistance in Plasmodium falciparum during treatment in a traveler in Comoros. Antimicrob. Agents Chemother.52(6), 2283–2284 (2008).
   PubMedGoogle Scholar
• Legrand E, Demar M, Volney B et al. A first case of Plasmodium falciparum atovaquone–proguanil treatment failure in French Guiana. Antimicrob. Agents Chemother.51(6), 2280–2281 (2007).
   PubMedGoogle Scholar
• Perry TL, Pandey P, Grant JM, Kain KC. Severe atovaquone-resistant Plasmodium falciparum malaria in a Canadian traveller returned from the Indian subcontinent. Open Med.3(1), e10–e16 (2009).
   Google Scholar
• Korsinczky M, Chen N, Kotecka B, Saul A, Rieckmann K, Cheng Q. Mutations in Plasmodium falciparum cytochrome b that are associated with atovaquone resistance are located at a putative drug-binding site. Antimicrob. Agents Chemother.44(8), 2100–2108 (2000).
   PubMed Web of Science ®Google Scholar
• Wichmann O, Muehlberger N, Jelinek T et al. Screening for mutations related to atovaquone/proguanil resistance in treatment failures and other imported isolates of Plasmodium falciparum in Europe. J. Infect. Dis.190(9), 1541–1546 (2004).
   PubMedGoogle Scholar
• Happi CT, Gbotosho GO, Folarin OA et al. Confirmation of emergence of mutations associated with atovaquone–proguanil resistance in unexposed Plasmodium falciparum isolates from Africa. Malar. J.5, 82 (2006).
   PubMedGoogle Scholar
• Musset L, Pradines B, Parzy D, Durand R, Bigot P, Le Bras J. Apparent absence of atovaquone/proguanil resistance in 477 Plasmodium falciparum isolates from untreated French travellers. J. Antimicrob. Chemother.57(1), 110–115 (2006).
   PubMedGoogle Scholar
• Ekala MT, Khim N, Legrand E et al. Sequence analysis of Plasmodium falciparum cytochrome b in multiple geographic sites. Malar. J.6, 164 (2007).
   PubMedGoogle Scholar
• Parola P, Pradines B, Simon F et al. Antimalarial drug susceptibility and point mutations associated with drug resistance in 248 Plasmodium falciparum isolates imported from Comoros to Marseille, France in 2004–2006. Am. J. Trop. Med. Hyg.77(3), 431–437 (2007).
   PubMed Web of Science ®Google Scholar
• Legrand E, Volney B, Meynard JB, Mercereau-Puijalon O, Esterre P. In vitro Monitoring of Plasmodium falciparum rug esistance in French Guiana: a synopsis of continuous assessment from 1994 to 2005. Antimicrob. Agents Chemother.52(1), 288–298 (2008).
   PubMed Web of Science ®Google Scholar
• Taylor WR, White NJ. Antimalarial drug toxicity: a review. Drug Saf.27(1), 25–61 (2004).
   PubMed Web of Science ®Google Scholar
• White NJ. Cardiotoxicity of antimalarial drugs. Lancet Infect. Dis.7(8), 549–558 (2007).
   PubMed Web of Science ®Google Scholar
• White NJ. Qinghaosu (artemisinin): the price of success. Science320(5874), 330–334 (2008).
   PubMed Web of Science ®Google Scholar
• White NJ. Antimalarial drug resistance. J. Clin. Invest.113(8), 1084–1092 (2004).
   PubMed Web of Science ®Google Scholar
• Nosten F, White NJ. Artemisinin-based combination treatment of falciparum malaria. Am. J. Trop. Med. Hyg.77(Suppl. 6), 181–192 (2007).
   PubMed Web of Science ®Google Scholar
• D’Alessandro U. Existing antimalarial agents and malaria-treatment strategies. Expert Opin. Pharmacother.10(8), 1291–1306 (2009).
   PubMed Web of Science ®Google Scholar
• Wernsdorfer WH. Coartemether (artemether and lumefantrine): an oral antimalarial drug. Expert Rev. Anti Infect. Ther.2(2), 181–196 (2004).
   PubMedGoogle Scholar
• Sinclair D, Zani B, Donegan S, Olliaro P, Garner P. Artemisinin-based combination therapy for treating uncomplicated malaria. Cochrane Database Syst. Rev.8(3), CD007483 (2009).
   Google Scholar
• Ashley EA, McGready R, Hutagalung R et al. A randomized, controlled study of a simple, once-daily regimen of dihydroartemisinin–piperaquine for the treatment of uncomplicated, multidrug-resistant falciparum malaria. Clin. Infect. Dis.41(4), 425–432 (2005).
   PubMed Web of Science ®Google Scholar
• Valecha N, Phyo AP, Mayxay M et al. An open-label, randomised study of dihydroartemisinin–piperaquine versus artesunate–mefloquine for falciparum malaria in Asia. PLoS ONE5(7), e11880 (2010).
   PubMed Web of Science ®Google Scholar
• Zwang J, Ashley EA, Karema C et al. Safety and efficacy of dihydroartemisinin–piperaquine in falciparum malaria: a prospective multi-centre individual patient data analysis. PLoS ONE4(7), e6358 (2009).
   PubMed Web of Science ®Google Scholar
• Ndiaye JL, Randrianarivelojosia M, Sagara I et al. Randomized, multicentre assessment of the efficacy and safety of ASAQ – a fixed-dose artesunate–amodiaquine combination therapy in the treatment of uncomplicated Plasmodium falciparum malaria. Malar. J.8, 125 (2009).
   PubMed Web of Science ®Google Scholar
• Tshefu AK, Gaye O, Kayentao K et al. Efficacy and safety of a fixed-dose oral combination of pyronaridine–artesunate compared with artemether–lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial. Lancet375(9724), 1457–1467 (2010).
   PubMed Web of Science ®Google Scholar
• Hombhanje FW, Linge D, Saweri A et al. Artemisinin–naphthoquine combination (ARCO) therapy for uncomplicated falciparum malaria in adults of Papua New Guinea: a preliminary report on safety and efficacy. Malar. J.8, 196 (2009).
   PubMedGoogle Scholar
• Laufer MK, Thesing PC, Eddington ND et al. Return of chloroquine antimalarial efficacy in Malawi. N. Engl. J. Med.355(19), 1959–1966 (2006).
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global report on antimalarial drug efficacy and drug resistance: 2000–2010. World Health Organization, Geneva, Switzerland (2010).
   Google Scholar
• Dondorp AM, Nosten F, Yi P et al. Artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med.361(5), 455–467 (2009).
   PubMed Web of Science ®Google Scholar
• Noedl H, Se Y, Sriwichai S et al. Artemisinin resistance in Cambodia: a clinical trial designed to address an emerging problem in southeast Asia. Clin. Infect. Dis.51(11), e82–e89 (2010).
   PubMed Web of Science ®Google Scholar
• Rogers WO, Sem R, Tero T et al. Failure of artesunate–mefloquine combination therapy for uncomplicated Plasmodium falciparum malaria in southern Cambodia. Malar. J.8, 10 (2009).
   PubMed Web of Science ®Google Scholar
• Dondorp AM, Yeung S, White L et al. Artemisinin resistance: current status and scenarios for containment. Nat. Rev. Microbiol.8(4), 272–280 (2010).
   PubMed Web of Science ®Google Scholar
• Newton PN, Fernandez FM, Plancon A et al. A collaborative epidemiological investigation into the criminal fake artesunate trade in South East Asia. PLoS Med.5(2), e32 (2008).
   PubMed Web of Science ®Google Scholar
• Wongsrichanalai C, Varma JK, Juliano JJ, Kimerling ME, MacArthur JR. Extensive drug resistance in malaria and tuberculosis. Emerg. Infect. Dis.16(7), 1063–1067 (2010).
   PubMedGoogle Scholar
• Shahinas D, Lau R, Khaimar K, Hancock D, Pillai DR. Artesunate misuse and Plasmodium falciparum malaria in a traveler returning from Africa. Emerg. Infect. Dis.16(10), 1608–1610 (2010).
   PubMedGoogle Scholar
• Dondorp AM, Day NP. The treatment of severe malaria. Trans. R. Soc. Trop. Med. Hyg.101(7), 633–634 (2007).
   PubMed Web of Science ®Google Scholar
• Dondorp AM, Nosten F, Stepniewska K, Day N, White N. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet366(9487), 717–725 (2005).
   PubMed Web of Science ®Google Scholar
• Dondorp AM, Fanello CI, Hendriksen ICE et al. Artesunate versus quinine in the treatment of severe falciparum malária in African children (AQUAMAT): an open-label, randomised trial. Lancet376(9753), 1647–1657 (2010).
   PubMed Web of Science ®Google Scholar
• Gomes MF, Faiz MA, Gyapong JO et al. Pre-referral rectal artesunate to prevent death and disability in severe malaria: a placebo-controlled trial. Lancet373(9663), 557–566 (2009).
   PubMed Web of Science ®Google Scholar
• Baird JK. Resistance to therapies for infection by Plasmodium vivax. Clin. Microbiol. Rev.22(3), 508–534 (2009).
   PubMed Web of Science ®Google Scholar
• Lacy MD, Maguire JD, Barcus MJ et al. Atovaquone/proguanil therapy for Plasmodium falciparum and Plasmodium vivax malaria in Indonesians who lack clinical immunity. Clin. Infect. Dis.35(9), e92–e95 (2002).
   Google Scholar
• Looareesuwan S, Wilairatana P, Glanarongran R et al. Atovaquone and proguanil hydrochloride followed by primaquine for treatment of Plasmodium vivax malaria in Thailand. Trans. R. Soc. Trop. Med. Hyg.93(6), 637–640 (1999).
   PubMed Web of Science ®Google Scholar
• Douglas NM, Anstey NM, Angus BJ, Nosten F, Price RN. Artemisinin combination therapy for vivax malaria. Lancet Infect. Dis.10(6), 405–416 (2010).
   PubMed Web of Science ®Google Scholar
• Ratcliff A, Siswantoro H, Kenangalem E et al. Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. Lancet369(9563), 757–765 (2007).
   PubMed Web of Science ®Google Scholar
• Bassat Q, Mulenga M, Tinto H et al. Dihydroartemisinin–piperaquine and artemether–lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial. PLoS ONE4(11), e7871 (2009).
   PubMed Web of Science ®Google Scholar
• Radloff PD, Philipps J, Hutchinson D, Kremsner PG. Atovaquone plus proguanil is an effective treatment for Plasmodium ovale and P. malariae malaria. Trans. R. Soc. Trop. Med. Hyg.90(6), 682 (1996).
   PubMed Web of Science ®Google Scholar
• Borrmann S, Szlezak N, Binder RK et al. Evidence for the efficacy of artesunate in asymptomatic Plasmodium malariae infections. J. Antimicrob. Chemother.50(5), 751–754 (2002).
   PubMed Web of Science ®Google Scholar
• Walsh DS, Wilairatana P, Tang DB et al. Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse. Clin. Infect. Dis.39(8), 1095–1103 (2004).
   PubMed Web of Science ®Google Scholar
• Daneshvar C, Davis TM, Cox-Singh J et al. Clinical and laboratory features of human Plasmodium knowlesi infection. Clin. Infect. Dis.49(6), 852–860 (2009).
   PubMedGoogle Scholar
• Jiang N, Chang Q, Sun X et al. Co-infections with Plasmodium knowlesi and other malaria parasites, Myanmar. Emerg. Infect. Dis.16(9), 1476–1478 (2010).
   PubMedGoogle Scholar
• Van den Eede P, Van HN, Van Overmeir C et al. Human Plasmodium knowlesi infections in young children in central Vietnam. Malar. J.8, 249 (2009).
   PubMedGoogle Scholar
• Centers for Disease Control. Simian malaria in a U.S. traveler – New York, 2008. MMWR Morb. Mortal. Wkly Rep.58(9), 229–232 (2009).
   PubMedGoogle Scholar
• Bronner U, Divis PC, Farnert A, Singh B. Swedish traveller with Plasmodium knowlesi malaria after visiting Malaysian Borneo. Malar. J.8, 15 (2009).
   PubMed Web of Science ®Google Scholar
• Kantele A, Marti H, Felger I, Muller D, Jokiranta TS. Monkey malaria in a European traveler returning from Malaysia. Emerg. Infect. Dis.14(9), 1434–1436 (2008).
   PubMedGoogle Scholar
• Ta TT, Salas A, li-Tammam M et al. First case of detection of Plasmodium knowlesi in Spain by real time PCR in a traveller from Southeast Asia. Malar. J.9, 219 (2010).
   PubMedGoogle Scholar
• van Hellemond JJ, Rutten M, Koelewijn R et al. Human Plasmodium knowlesi infection detected by rapid diagnostic tests for malaria. Emerg. Infect. Dis.15(9), 1478–1480 (2009).
   PubMedGoogle Scholar
• Franco-Paredes C, Santos-Preciado JI. Problem pathogens: prevention of malaria in travellers. Lancet Infect. Dis.6(3), 139–149 (2006).
   PubMed Web of Science ®Google Scholar
• Griffith KS, Lewis LS, Mali S, Parise ME. Treatment of malaria in the United States: a systematic review. JAMA297(20), 2264–2277 (2007).
   PubMed Web of Science ®Google Scholar
• Hatz C, Soto J, Nothdurft HD et al. Treatment of acute uncomplicated falciparum malaria with artemether–lumefantrine in nonimmune populations: a safety, efficacy, and pharmacokinetic study. Am. J. Trop. Med. Hyg.78(2), 241–247 (2008).
   PubMed Web of Science ®Google Scholar
• Lalloo DG, Shingadia D, Pasvol G et al. UK malaria treatment guidelines. J. Infect.54(2), 111–121 (2007).
   PubMed Web of Science ®Google Scholar
• Committee to Advise on Tropical Medicine and Travel (CATMAT). Canadian recommendations for the prevention and treatment of malaria among international travellers – 2009. Can. Commun. Dis. Rep.35(Suppl. 1), 1–82 (2009).
   PubMedGoogle Scholar
• CDC. Malaria Guidelines for Health Professionals in the Northern Territory, 5th Edition. CDC, Atlanta, GA, USA (2007).
   Google Scholar
• Ward SA, Sevene EJ, Hastings IM, Nosten F, McGready R. Antimalarial drugs and pregnancy: safety, pharmacokinetics, and pharmacovigilance. Lancet Infect. Dis.7(2), 136–144 (2007).
   PubMed Web of Science ®Google Scholar
• Nosten F, McGready R, Mutabingwa T. Case management of malaria in pregnancy. Lancet Infect. Dis.7(2), 118–125 (2007).
   PubMed Web of Science ®Google Scholar
• Bethell D, Se Y, Lon C et al. Dose-dependant risk of neutropenia after 7-day courses of artesunate monotherapy in Cambodian patients with acute Plasmodium falciparum malaria. Clin. Infect. Dis.51(12), e105–e114 (2010).
   Google Scholar
• Adjei GO, Goka BQ, Binka F, Kurtzhals JA. Artemether–lumefantrine: an oral antimalarial for uncomplicated malaria in children. Expert Rev. Anti Infect. Ther.7(6), 669–681 (2009).
   PubMed Web of Science ®Google Scholar
• McGready R, Cho T, Keo NK et al. Artemisinin antimalarials in pregnancy: a prospective treatment study of 539 episodes of multidrug-resistant Plasmodium falciparum. Clin. Infect. Dis.33(12), 2009–2016 (2001).
   PubMed Web of Science ®Google Scholar
• McGready R, Tan SO, Ashley EA et al. A randomised controlled trial of artemether–lumefantrine versus artesunate for uncomplicated Plasmodium falciparum treatment in pregnancy. PLoS Med.5(12), e253 (2008).
   PubMed Web of Science ®Google Scholar
• Wongsrichanalai C, Pickard AL, Wernsdorfer WH, Meshnick SR. Epidemiology of drug-resistant malaria. Lancet Infect. Dis.2(4), 209–218 (2002).
   PubMed Web of Science ®Google Scholar
• Pradines B, Pistone T, Ezzedine K et al. Quinine-resistant malaria in traveler returning from Senegal, 2007. Emerg. Infect. Dis.16(3), 546–548 (2010).
   PubMedGoogle Scholar
• Miller RS, Wongsrichanalai C, Buathong N et al. Effective treatment of uncomplicated Plasmodium falciparum malaria with azithromycin-quinine combinations: a randomized, dose-ranging study. Am. J. Trop. Med. Hyg.74(3), 401–406 (2006).
   PubMed Web of Science ®Google Scholar
• Adegnika AA, Breitling LP, Agnandji ST et al. Effectiveness of quinine monotherapy for the treatment of Plasmodium falciparum infection in pregnant women in Lambarene, Gabon. Am. J. Trop. Med. Hyg.73(2), 263–266 (2005).
   PubMed Web of Science ®Google Scholar
• D’Acremont V, Landry P, Darioli R et al. Treatment of imported malaria in an ambulatory setting: prospective study. Br. Med. J.324(7342), 875–877 (2002).
   PubMedGoogle Scholar
• Melzer M, Lacey S, Rait G. The case for outpatient treatment of Plasmodium falciparum malaria in a selected UK immigrant population. J. Infect.59(4), 259–263 (2009).
   PubMedGoogle Scholar
• Jelinek T. Intravenous artesunate recommended for patients with severe malaria: position statement from TropNetEurop. Euro Surveill.10(11), E051124 (2005).
   Google Scholar
• Shanks GD. For severe malaria, arstesunate is the answer. Lancet376, 1621–1622 (2010).
   PubMedGoogle Scholar
• Rosenthal PJ. Artesunate for the treatment of severe falciparum malaria. N. Engl. J. Med.358(17), 1829–1836 (2008).
   PubMed Web of Science ®Google Scholar
• Morch K, Strand O, Dunlop O et al. Severe malaria and artesunate treatment, Norway. Emerg. Infect. Dis.14(11), 1816–1818 (2008).
   PubMed Web of Science ®Google Scholar
• Bartoloni A, Tomasoni L, Bartalesi F et al. Combined intravenous treatment with artesunate and quinine for severe malaria in Italy. Am. J. Trop. Med. Hyg.83(2), 274–276 (2010).
   PubMed Web of Science ®Google Scholar
• Newton PN, Chierakul W, Ruangveerayuth R et al. A comparison of artesunate alone with combined artesunate and quinine in the parenteral treatment of acute falciparum malaria. Trans. R. Soc. Trop. Med. Hyg.95(5), 519–523 (2001).
   PubMedGoogle Scholar
• John CC, Kutamba E, Mugarura K, Opoka RO. Adjunctive therapy for cerebral malaria and other severe forms of Plasmodium falciparum malaria. Expert Rev. Anti Infect. Ther.8(9), 997–1008 (2010).
   PubMed Web of Science ®Google Scholar
• Bottieau E, Clerinx J, Van den Enden E et al. Imported non-Plasmodium falciparum malaria: a five-year prospective study in a European referral center. Am. J. Trop. Med. Hyg.75(1), 133–138 (2006).
   PubMed Web of Science ®Google Scholar
• White NJ. Plasmodium knowlesi: the fifth human malaria parasite. Clin. Infect. Dis.46(2), 172–173 (2008).
   PubMed Web of Science ®Google Scholar
• Daneshvar C, Davis TM, Cox-Singh J et al. Clinical and parasitological response to oral chloroquine and primaquine in uncomplicated human Plasmodium knowlesi infections. Malar. J.9(1), 238 (2010).
   PubMed Web of Science ®Google Scholar
• Murray HW, Berman JD, Davies CR, Saravia NG. Advances in leishmaniasis. Lancet366(9496), 1561–1577 (2005).
   PubMed Web of Science ®Google Scholar
• Desjeux P. Leishmaniasis. Nat. Rev. Microbiol.2(9), 692 (2004).
   PubMedGoogle Scholar
• Caumes E, Carriere J, Guermonprez G et al. Dermatoses associated with travel to tropical countries: a prospective study of the diagnosis and management of 269 patients presenting to a tropical disease unit. Clin. Infect. Dis.20(3), 542–548 (1995).
   PubMed Web of Science ®Google Scholar
• Blum J, Desjeux P, Schwartz E, Beck B, Hatz C. Treatment of cutaneous leishmaniasis among travellers. J. Antimicrob. Chemother.53(2), 158–166 (2004).
   PubMedGoogle Scholar
• Schwartz E, Hatz C, Blum J. New world cutaneous leishmaniasis in travellers. Lancet Infect. Dis.6(6), 342–349 (2006).
   PubMed Web of Science ®Google Scholar
• Scope A, Trau H, Bakon M et al. Imported mucosal leishmaniasis in a traveler. Clin. Infect. Dis.37(6), e83–e87 (2003).
   Google Scholar
• Malik ANJ, John L, Bryceson ADM, Lockwood DNJ. Changing pattern of visceral leishmaniasis, United Kingdom, 1985–2004. Emerg. Infect. Dis.12(8), 1257–1259 (2006).
   PubMed Web of Science ®Google Scholar
• Perez-Ayala A, Norman F, Perez-Molina JA et al. Imported leishmaniasis: a heterogeneous group of diseases. J. Travel. Med.16(6), 395–401 (2009).
   PubMed Web of Science ®Google Scholar
• Rijal S, Boelaert M, Regmi S et al. Evaluation of a urinary antigen-based latex agglutination test in the diagnosis of kala-azar in eastern Nepal. Trop. Med. Int. Health9(6), 724–729 (2004).
   PubMedGoogle Scholar
• Boelaert M, Rijal S, Regmi S et al. A comparative study of the effectiveness of diagnostic tests for visceral leishmaniasis. Am. J. Trop. Med. Hyg.70(1), 72–77 (2004).
   PubMed Web of Science ®Google Scholar
• Chappuis F, Rijal S, Singh R et al. Prospective evaluation and comparison of the direct agglutination test and an rK39-antigen-based dipstick test for the diagnosis of suspected kala-azar in Nepal. Trop. Med. Int. Health8(3), 277–285 (2003).
   PubMedGoogle Scholar
• Reithinger R, Dujardin JC. Molecular diagnosis of leishmaniasis: current status and future applications. J. Clin. Microbiol.45(1), 21–25 (2007).
   PubMed Web of Science ®Google Scholar
• Goto H, Lindoso JA. Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis. Expert Rev. Anti Infect. Ther.8(4), 419–433 (2010).
   PubMed Web of Science ®Google Scholar
• Mondal S, Bhattacharya P, Ali N. Current diagnosis and treatment of visceral leishmaniasis. Expert Rev. Anti Infect. Ther.8(8), 919–944 (2010).
   PubMed Web of Science ®Google Scholar
• Reithinger R, Dujardin JC, Louzir H et al. Cutaneous leishmaniasis. Lancet Infect. Dis.7(9), 581–596 (2007).
   PubMed Web of Science ®Google Scholar
• WHO Technical Report Series 949. Control of the Leishmaniases. Presented at: WHO Expert Committee on the Control of Leishmaniases. Geneva, Switzerland, 22–26 March 2010.
   Google Scholar
• Sundar S, Agrawal G, Rai M, Makharia MK, Murray HW. Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial. Br. Med. J.323(7310), 419–422 (2001).
   PubMed Web of Science ®Google Scholar
• den Boer M, Davidson RN. Treatment options for visceral leishmaniasis. Expert Rev. Anti Infect. Ther.4(2), 187–197 (2006).
   PubMedGoogle Scholar
• Kim DH, Chung HJ, Bleys J, Ghohestani RF. Is paromomycin an effective and safe treatment against cutaneous leishmaniasis? A meta-analysis of 14 randomized controlled trials. PLoS Negl. Trop. Dis.3(2), e381 (2009).
   PubMed Web of Science ®Google Scholar
• Gonzalez U, Pinart M, Rengifo-Pardo M et al. Interventions for American cutaneous and mucocutaneous leishmaniasis. Cochrane Database Syst. Rev.15(2), CD004834 (2009).
   Google Scholar
• Gonzalez U, Pinart M, Reveiz L, Alvar J. Interventions for Old World cutaneous leishmaniasis. Cochrane Database Syst. Rev.8(4), CD005067 (2008).
   Google Scholar
• Arevalo J, Ramirez L, Adaui V et al. Influence of Leishmania (Viannia) species on the response to antimonial treatment in patients with American tegumentary leishmaniasis. J. Infect. Dis.195(12), 1846–1851 (2007).
   PubMed Web of Science ®Google Scholar
• Llanos-Cuentas A, Tulliano G, raujo-Castillo R et al. Clinical and parasite species risk factors for pentavalent antimonial treatment failure in cutaneous leishmaniasis in Peru. Clin. Infect. Dis.46(2), 223–231 (2008).
   PubMedGoogle Scholar
• Alvar J, Aparicio P, Aseffa A et al. The relationship between leishmaniasis and AIDS: the second 10 years. Clin. Microbiol. Rev.21(2), 334–359 (2008).
   PubMed Web of Science ®Google Scholar
• Dorlo TP, van Thiel PP, Huitema AD et al. Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients. Antimicrob. Agents Chemother.52(8), 2855–2860 (2008).
   PubMed Web of Science ®Google Scholar
• Sundar S, Jha TK, Sindermann H et al. Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis. Pediatr. Infect. Dis. J.22(5), 434–438 (2003).
   PubMed Web of Science ®Google Scholar
• Sundar S, Jha TK, Thakur CP et al. Oral miltefosine for Indian visceral leishmaniasis. N. Engl. J. Med.347(22), 1739–1746 (2002).
   PubMed Web of Science ®Google Scholar
• Ritmeijer K, Dejenie A, Assefa Y et al. A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection. Clin. Infect. Dis.43(3), 357–364 (2006).
   PubMed Web of Science ®Google Scholar
• Bhattacharya SK, Sinha PK, Sundar S et al. Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis. J. Infect. Dis.196(4), 591–598 (2007).
   PubMed Web of Science ®Google Scholar
• Mohebali M, Fotouhi A, Hooshmand B et al. Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran. Acta Trop.103(1), 33–40 (2007).
   PubMed Web of Science ®Google Scholar
• van Thiel PP, Leenstra T, Kager PA et al. Miltefosine treatment of Leishmania major infection: an observational study involving Dutch military personnel returning from northern Afghanistan. Clin. Infect. Dis.50(1), 80–83 (2010).
   PubMedGoogle Scholar
• Keynan Y, Larios OE, Wiseman MC et al. Use of oral miltefosine for cutaneous leishmaniasis in Canadian soldiers returning from Afghanistan. Can. J. Infect. Dis. Med. Microbiol.19(6), 394–396 (2008).
   PubMed Web of Science ®Google Scholar
• Soto J, Rea J, Balderrama M et al. Efficacy of miltefosine for Bolivian cutaneous leishmaniasis. Am. J. Trop. Med. Hyg.78(2), 210–211 (2008).
   PubMed Web of Science ®Google Scholar
• Soto J, Toledo J, Valda L et al. Treatment of Bolivian mucosal leishmaniasis with miltefosine. Clin. Infect. Dis.44(3), 350–356 (2007).
   PubMed Web of Science ®Google Scholar
• Seifert K, Matu S, Javier Perez-Victoria F et al. Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine). Int. J. Antimicrob. Agents22(4), 380–387 (2003).
   PubMed Web of Science ®Google Scholar
• Pandey BD, Pandey K, Kaneko O, Yanagi T, Hirayama K. Relapse of visceral leishmaniasis after miltefosine treatment in a Nepalese patient. Am. J. Trop. Med. Hyg.80(4), 580–582 (2009).
   PubMed Web of Science ®Google Scholar
• Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK. Injectable paromomycin for Visceral leishmaniasis in India. N. Engl. J. Med.356(25), 2571–2581 (2007).
   PubMed Web of Science ®Google Scholar
• Sundar S, Agrawal N, Arora R et al. Short-course paromomycin treatment of visceral leishmaniasis in India: 14-day vs 21-day treatment. Clin. Infect. Dis.49(6), 914–918 (2009).
   PubMed Web of Science ®Google Scholar
• Musa AM, Younis B, Fadlalla A et al. Paromomycin for the treatment of visceral leishmaniasis in Sudan: a randomized, open-label, dose-finding study. PLoS Negl. Trop. Dis.4(10), e855 (2010).
   PubMed Web of Science ®Google Scholar
• Bern C, Adler-Moore J, Berenguer J et al. Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin. Infect. Dis.43(7), 917–924 (2006).
   PubMed Web of Science ®Google Scholar
• Sundar S, Chakravarty J, Rai VK et al. Amphotericin B treatment for Indian visceral leishmaniasis: response to 15 daily versus alternate-day infusions. Clin. Infect. Dis.45(5), 556–561 (2007).
   PubMedGoogle Scholar
• Sundar S, Jha TK, Thakur CP et al. Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study. Clin. Infect. Dis.37(6), 800–804 (2003).
   PubMed Web of Science ®Google Scholar
• Sundar S, Chakravarty J, Agarwal D, Rai M, Murray HW. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N. Engl. J. Med.362(6), 504–512 (2010).
   PubMed Web of Science ®Google Scholar
• Mueller M, Ritmeijer K, Balasegaram M et al. Unresponsiveness to AmBisome in some Sudanese patients with kala-azar. Trans. R. Soc. Trop. Med. Hyg.101(1), 19–24 (2007).
   PubMed Web of Science ®Google Scholar
• Laguna F, Videla S, Jimenez-Mejias ME et al. Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study. J. Antimicrob. Chemother.52(3), 464–468 (2003).
   PubMed Web of Science ®Google Scholar
• Chappuis F, Sundar S, Hailu A et al. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat. Rev. Microbiol.5(11), 873–882 (2007).
   PubMed Web of Science ®Google Scholar
• Olliaro PL. Drug combinations for visceral leishmaniasis. Curr. Opin. Infect. Dis.23(6), 595–602 (2010).
   PubMedGoogle Scholar
• Thakur CP, Kanyok TP, Pandey AK et al. A prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis. Trans. R. Soc. Trop. Med. Hyg.94(4), 429–431 (2000).
   PubMed Web of Science ®Google Scholar
• Melaku Y, Collin SM, Keus K et al. Treatment of kala-azar in southern Sudan using a 17-day regimen of sodium stibogluconate combined with paromomycin: a retrospective comparison with 30-day sodium stibogluconate monotherapy. Am. J. Trop. Med. Hyg.77(1), 89–94 (2007).
   PubMed Web of Science ®Google Scholar
• Sundar S, Rai M, Chakravarty J et al. New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine. Clin. Infect. Dis.47(8), 1000–1006 (2008).
   PubMed Web of Science ®Google Scholar
• van Griensven J, Balasegaram M, Meheus F et al. Combination therapy for visceral leishmaniasis. Lancet Infect. Dis.10(3), 184–194 (2010).
   PubMed Web of Science ®Google Scholar
• Blum JA, Hatz CF. Treatment of cutaneous leishmaniasis in travelers 2009. J. Travel. Med.16(2), 123–131 (2009).
   PubMed Web of Science ®Google Scholar
• Khatami A, Firooz A, Gorouhi F, Dowlati Y. Treatment of acute Old World cutaneous leishmaniasis: a systematic review of the randomized controlled trials. J. Am. Acad. Dermatol.57(2), 335–329 (2007).
   PubMed Web of Science ®Google Scholar
• Roussel M, Nacher M, Fremont G et al. Comparison between one and two injections of pentamidine isethionate, at 7 mg/kg in each injection, in the treatment of cutaneous leishmaniasis in French Guiana. Ann. Trop. Med. Parasitol.100(4), 307–314 (2006).
   PubMed Web of Science ®Google Scholar
• Nacher M, Carme B, Sainte MD et al. Influence of clinical presentation on the efficacy of a short course of pentamidine in the treatment of cutaneous leishmaniasis in French Guiana. Ann. Trop. Med. Parasitol.95(4), 331–336 (2001).
   PubMed Web of Science ®Google Scholar
• Moudgal VV, Sobel JD. Antifungal drugs in pregnancy: a review. Expert Opin. Drug Saf.2(5), 475–483 (2003).
   PubMedGoogle Scholar
• Antinori S, Cascio A, Parravicini C, Bianchi R, Corbellino M. Leishmaniasis among organ transplant recipients. Lancet Infect. Dis.8, 191–199 (2008).
   PubMed Web of Science ®Google Scholar
• Sindermann H, Engel J. Development of miltefosine as an oral treatment for leishmaniasis. Trans. R. Soc. Trop. Med. Hyg.100(Suppl. 1), S17–S20 (2006).
   PubMed Web of Science ®Google Scholar
• Sindermann H, Engel KR, Fischer C, Bommer W. Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection. Clin. Infect. Dis.39(10), 1520–1523 (2004).
   PubMed Web of Science ®Google Scholar
• Lopez-Velez R, Videal S, Marquez M et al. Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients. J. Antimicrob. Chemother.53(3), 540–543 (2004).
   PubMed Web of Science ®Google Scholar
• Pepin J, Meda HA. The Epidemiology and control of human African trypanosomiasis. Adv. Parasitol.49, 71–132 (2001).
   PubMed Web of Science ®Google Scholar
• Blum J, Schmid C, Burri C. Clinical aspects of 2541 patients with second stage human African trypanosomiasis. Acta Trop.97(1), 55–64 (2006).
   PubMedGoogle Scholar
• Chappuis F, Loutan L, Simarro P, Lejon V, Buscher P. Options for field diagnosis of human african trypanosomiasis. Clin. Microbiol. Rev.18(1), 133–146 (2005).
   PubMed Web of Science ®Google Scholar
• Lejon V, Buscher P. Review Article: cerebrospinal fluid in human African trypanosomiasis: a key to diagnosis, therapeutic decision and post-treatment follow-up. Trop. Med. Int. Health10(5), 395–403 (2005).
   PubMed Web of Science ®Google Scholar
• Lejon V, Legros D, Savignoni A et al. Neuro-inflammatory risk factors for treatment failure in “early second stage” sleeping sickness patients treated with pentamidine. J. Neuroimmunol.144(1–2), 132–138 (2003).
   PubMedGoogle Scholar
• Gautret P, Clerinx J, Caumes E et al. Imported human African trypanosomiasis in Europe, 2005–2009. Euro Surveill.14(36), pii: 19327 (2009).
   Google Scholar
• Lejon V, Boelaert M, Jannin J, Moore A, Buscher P. The challenge of Trypanosoma brucei gambiense sleeping sickness diagnosis outside Africa. Lancet Infect. Dis.3(12), 804–808 (2003).
   PubMedGoogle Scholar
• Deborggraeve S, Buscher P. Molecular diagnostics for sleeping sickness: what is the benefit for the patient? Lancet Infect. Dis.10(6), 433–439 (2010).
   PubMed Web of Science ®Google Scholar
• Legros D, Ollivier G, Gastellu-Etchegorry M et al. Treatment of human African trypanosomiasis – present situation and needs for research and development. Lancet Infect. Dis.2(7), 437–440 (2002).
   PubMed Web of Science ®Google Scholar
• Burri C. Chemotherapy against human African trypanosomiasis: is there a road to success? Parasitology137, 1987–1994 (2010).
   PubMed Web of Science ®Google Scholar
• Burri C, Nkunku S, Merolle A et al. Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial. Lancet355(9213), 1419–1425 (2000).
   PubMedGoogle Scholar
• Schmid C, Richer M, Bilenge CM et al. Effectiveness of a 10-day melarsoprol schedule for the treatment of late-stage human African trypanosomiasis: confirmation from a multinational study (IMPAMEL II). J. Infect. Dis.191, 1922–1931 (2005).
   PubMed Web of Science ®Google Scholar
• Blum J, Nkunku S, Burri C. Clinical description of encephalopathic syndromes and risk factors for their occurrence and outcome during melarsoprol treatment of human African trypanosomiasis. Trop. Med. Int. Health6(5), 390–400 (2001).
   PubMed Web of Science ®Google Scholar
• Pepin J, Milord F, Guern C et al. Trial of prednisolone for prevention of melarsoprol-induced encephalopathy in gambiense sleeping sickness. Lancet1(8649), 1246–1250 (1989).
   PubMed Web of Science ®Google Scholar
• Blum JA, Zellweger MJ, Burri C, Hatz C. Cardiac involvement in African and American trypanosomiasis. Lancet Infect. Dis.8, 631–641 (2008).
   PubMed Web of Science ®Google Scholar
• Clerinx J, Taelman H, Bogaerts J, Vervoort T. Treatment of late stage rhodesiense trypanosomiasis using suramin and eflornithine: report of six cases. Trans. R. Soc. Trop. Med. Hyg.92(4), 449–450 (1998).
   PubMedGoogle Scholar
• Chappuis F, Udayraj N, Stietenroth K, Meussen A, Bovier PA. Eflornithine is safer than melarsoprol for the treatment of second-stage Trypanosoma brucei gambiense human African trypanosomiasis. Clin. Infect. Dis.41(5), 748–751 (2005).
   PubMed Web of Science ®Google Scholar
• Milord F, Pepin J, Loko L, Ethier L, Mpia B. Efficacy and toxicity of eflornithine for treatment of Trypanosoma brucei gambiense sleeping sickness. Lancet340(8820), 652–655 (1992).
   PubMed Web of Science ®Google Scholar
• Pepin J, Khonde N, Maiso F et al. Short-course eflornithine in Gambian trypanosomiasis: a multicentre randomized controlled trial. Bull. World Health Organ.78(11), 1284–1295 (2000).
   PubMedGoogle Scholar
• Priotto G, Kasparian S, Ngouama D et al. Nifurtimox–eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Congo. Clin. Infect. Dis.45(11), 1435–1442 (2007).
   PubMed Web of Science ®Google Scholar
• Bisser S, N’siesi FX, Lejon V et al. Equivalence trial of melarsoprol and nifurtimox monotherapy and combination therapy for the treatment of second-stage Trypanosoma brucei gambiense sleeping sickness. J. Infect. Dis.195(3), 322–329 (2007).
   PubMed Web of Science ®Google Scholar
• Chappuis F. Melarsoprol-free drug combinations for second-stage Gambian sleeping sickness: the way to go. Clin. Infect. Dis.45(11), 1443–1445 (2007).
   PubMed Web of Science ®Google Scholar
• Balasegaram M, Harris S, Checchi F et al. Melarsoprol versus eflornithine for treating late-stage Gambian trypanosomiasis in the Republic of the Congo. Bull. World Health Organ.84(10), 783–791 (2006).
   PubMedGoogle Scholar
• Balasegaram M, Young H, Chappuis F et al. Effectiveness of melarsoprol and eflornithine as first-line regimens for gambiense sleeping sickness in nine Medecins Sans Frontieres programmes. Trans. R. Soc. Trop. Med. Hyg.103(3), 280–290 (2009).
   PubMed Web of Science ®Google Scholar
• Priotto G, Kasparian S, Mutombo W et al. Nifurtimox–eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, Phase III, non-inferiority trial. Lancet374(9683), 56–64 (2009).
   PubMed Web of Science ®Google Scholar
• Lutje V, Seixas J, Kennedy A. Chemotherapy for second-stage human African trypanosomiasis. Cochrane Database Syst. Rev.8, CD006201 (2010).
   Google Scholar
• Lejon V, Roger I, Mumba ND et al. Novel markers for treatment outcome in late-stage Trypanosoma brucei gambiense trypanosomiasis. Clin. Infect. Dis.47(1), 15–22 (2008).
   PubMedGoogle Scholar
• Mumba ND, Lejon V, N’siesi FX, Boelaert M, Buscher P. Comparison of operational criteria for treatment outcome in gambiense human African trypanosomiasis. Trop. Med. Int. Health14(4), 438–444 (2009).
   PubMedGoogle Scholar
• Mumba ND, Lejon V, Pyana P et al. How to shorten patient follow-up after treatment for Trypanosoma brucei gambiense sleeping sickness. J. Infect. Dis.201(3), 453–463 (2010).
   PubMedGoogle Scholar
• Rassi A Jr, Rassi A, Marin-Neto JA. Chagas disease. Lancet375(9723), 1388–1402 (2010).
   PubMed Web of Science ®Google Scholar
• Bern C, Montgomery SP. An estimate of the burden of Chagas disease in the United States. Clin. Infect. Dis.49(5), e52–e54 (2009).
   PubMed Web of Science ®Google Scholar
• Gascon J, Bern C, Pinazo MJ. Chagas disease in Spain, the United States and other non-endemic countries. Acta Trop.115(1–2), 22–27 (2010).
   PubMed Web of Science ®Google Scholar
• Jackson Y, Getaz L, Wolff H et al. Prevalence, clinical staging and risk for blood-borne transmission of Chagas disease among Latin American migrants in Geneva, Switzerland. PLoS Negl. Trop. Dis.4(2), e592 (2010).
   PubMedGoogle Scholar
• Munoz J, Coll O, Juncosa T et al. Prevalence and vertical transmission of Trypanosoma cruzi infection among pregnant Latin American women attending 2 maternity clinics in Barcelona, Spain. Clin. Infect. Dis.48(12), 1736–1740 (2009).
   PubMed Web of Science ®Google Scholar
• Piron M, Verges M, Munoz J et al. Seroprevalence of Trypanosoma cruzi infection in at-risk blood donors in Catalonia (Spain). Transfusion48(9), 1862–1868 (2008).
   PubMed Web of Science ®Google Scholar
• Bern C, Montgomery SP, Katz L, Caglioti S, Stramer SL. Chagas disease and the US blood supply. Curr. Opin. Infect. Dis.21(5), 476–482 (2008).
   PubMedGoogle Scholar
• Bowling J, Walter EA. Recognizing and meeting the challenge of Chagas disease in the USA. Expert Rev. Anti Infect. Ther.7(10), 1223–1234 (2009).
   PubMed Web of Science ®Google Scholar
• World Health Organization. Control and Prevention of Chagas Disease in Europe. Report of a WHO Informal Consultation, Geneva, Switzerland, 17–18 December 2009 (2010).
   Google Scholar
• Lescure FX, Canestri A, Melliez H et al. Chagas disease, France. Emerg. Infect. Dis.14(4), 644–646 (2008).
   PubMedGoogle Scholar
• Brisseau JM, Cebron JP, Petit T et al. Chagas myocarditis imported into France. Lancet1(8593), 1046 (1988).
   PubMedGoogle Scholar
• Bern C, Montgomery SP, Herwaldt BL et al. Evaluation and treatment of chagas disease in the United States: a systematic review. JAMA298(18), 2171–2181 (2007).
   PubMed Web of Science ®Google Scholar
• de Andrade AL, Zicker F, de Oliveira RM et al. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet348(9039), 1407–1413 (1996).
   PubMed Web of Science ®Google Scholar
• Sosa ES, Segura EL, Ruiz AM et al. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas disease. Am. J. Trop. Med. Hyg.59(4), 526–529 (1998).
   PubMed Web of Science ®Google Scholar
• Viotti R, Vigliano C, Armenti H, Segura E. Treatment of chronic Chagas disease with benznidazole: clinical and serologic evolution of patients with long-term follow-up. Am. Heart J.127(1), 151–162 (1994).
   PubMed Web of Science ®Google Scholar
• Villar JC, Marin-Neto JA, Ebrahim S, Yusuf S. Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection. Cochrane Database Syst. Rev. (1), CD003463 (2002).
   Google Scholar
• Reyes PA, Vallejo M. Trypanocidal drugs for late stage, symptomatic Chagas disease (Trypanosoma cruzi infection). Cochrane Database Syst. Rev.19(4), CD004102 (2005).
   Google Scholar
• Chappuis F, Mauris A, Holst M et al. Validation of a rapid immunochromatographic assay for diagnosis of Trypanosoma cruzi infection among Latin-American migrants in Geneva, Switzerland. J. Clin. Microbiol.48(8), 2948–2952 (2010).
   PubMedGoogle Scholar
• Deborggraeve S, Coronado X, Solari A et al. T. cruzi OligoC-TesT: a simplified and standardized polymerase chain reaction format for diagnosis of Chagas disease. PLoS Negl. Trop. Dis.3(6), e450 (2009).
   PubMed Web of Science ®Google Scholar
• Bern C, Verastegui M, Gilman RH et al. Congenital Trypanosoma cruzi transmission in Santa Cruz, Bolivia. Clin. Infect. Dis.49(11), 1667–1674 (2009).
   PubMed Web of Science ®Google Scholar
• Fitzwater S, Calderon M, Lafuente C et al. Polymerase chain reaction for chronic Trypanosoma cruzi infection yields higher sensitivity in blood clot than buffy coat or whole blood specimens. Am. J. Trop. Med. Hyg.79(5), 768–770 (2008).
   PubMed Web of Science ®Google Scholar
• Viotti R, Vigliano C. Etiological treatment of chronic Chagas disease: neglected ‘evidence’ by evidence-based medicine. Expert Rev. Anti Infect. Ther.5(4), 717–726 (2007).
   PubMed Web of Science ®Google Scholar
• Moncayo A, Ortiz Yanine MI. An update on Chagas disease (human American trypanosomiasis). Ann. Trop. Med. Parasitol.100(8), 663–677 (2006).
   PubMed Web of Science ®Google Scholar
• Laucella SA, Mazliah DP, Bertocchi G et al. Changes in Trypanosoma cruzi-specific immune responses after treatment: surrogate markers of treatment efficacy. Clin. Infect. Dis.49(11), 1675–1684 (2009).
   PubMed Web of Science ®Google Scholar
• Urbina JA. Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches. Acta Trop.115(1–2), 55–68 (2010).
   PubMed Web of Science ®Google Scholar
• Viotti R, Vigliano C, Lococo B et al. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann. Intern. Med.144(10), 724–734 (2006).
   PubMed Web of Science ®Google Scholar
• Viotti R, Vigliano C, Lococo B et al. Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities. Expert Rev. Anti Infect. Ther.7(2), 157–163 (2009).
   PubMed Web of Science ®Google Scholar
• Sosa-Estani S, Segura EL. Etiological treatment in patients infected by Trypanosoma cruzi: experiences in Argentina. Curr. Opin. Infect. Dis.19(6), 583–587 (2006).
   PubMed Web of Science ®Google Scholar
• Marin-Neto JA, Rassi A Jr, Morillo CA et al. Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas’ cardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT). Am. Heart J.156(1), 37–43 (2008).
   PubMed Web of Science ®Google Scholar
• Rassi A, Luquetti AO, Rassi A Jr et al. Specific treatment for Trypanosoma cruzi: lack of efficacy of allopurinol in the human chronic phase of Chagas disease. Am. J. Trop. Med. Hyg.76(1), 58–61 (2007).
   PubMed Web of Science ®Google Scholar
• Apt W, Arribada A, Zulantay I et al. Itraconazole or allopurinol in the treatment of chronic American trypanosomiasis: the results of clinical and parasitological examinations 11 years post-treatment. Ann. Trop. Med. Parasitol.99(8), 733–741 (2005).
   PubMed Web of Science ®Google Scholar
• Coura JR. Present situation and new strategies for Chagas disease chemotherapy: a proposal. Mem. Inst. Oswaldo Cruz104(4), 549–554 (2009).
   PubMedGoogle Scholar
• Urbina JA, Docampo R. Specific chemotherapy of Chagas disease: controversies and advances. Trends Parasitol.19(11), 495–501 (2003).
   PubMed Web of Science ®Google Scholar
• Jackson Y, Alirol E, Getaz L et al. Tolerance and safety of nifurtimox in patients with chronic Chagas disease. Clin. Infect. Dis.51(10), e69–e75 (2010).
   PubMed Web of Science ®Google Scholar
• Prata A. Clinical and epidemiological aspects of Chagas disease. Lancet Infect. Dis.1(2), 92–100 (2001).
   PubMedGoogle Scholar
• Rottmann M, McNamara C, Yeung BK et al. Spiroindolones, a potent compound class for the treatment of malaria. Science329(5996), 1175–1180 (2010).
   PubMed Web of Science ®Google Scholar
• Gonzalez U, Pinart M, Reveiz L et al. Designing and reporting clinical trials on treatments for cutaneous leishmaniasis. Clin. Infect. Dis.51(4), 409–419 (2010).
   PubMed Web of Science ®Google Scholar
• Yun O, Priotto G, Tong J, Flevaud L, Chappuis F. NECT is next: implementing the new drug combination therapy for Trypanosoma brucei gambiense sleeping sickness. PLoS Negl. Trop. Dis.4(5), e720 (2010).
   PubMed Web of Science ®Google Scholar
• Ribeiro I, Sevcsik AM, Alves F et al. New, improved treatments for Chagas disease: from the R&D pipeline to the patients. PLoS Negl. Trop. Dis.3(7), e484 (2009).
   PubMed Web of Science ®Google Scholar